Try Fund Library Premium
For Free with a 30 day trial!
Health Care Equity
Click for more information on Fundata’s FundGrade
Click for more information on Fundata’s FundGrade.
|
NAVPS (04-22-2026) |
$22.76 |
|---|---|
| Change |
$0.04
(0.18%)
|
As at March 31, 2026
As at March 31, 2026
Loading......
Inception Return (October 20, 2015): 8.03%
| Row Heading | Return | Annualized Return | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Mth | 3 Mth | 6 Mth | YTD | 1 Yr | 2 Yr | 3 Yr | 4 Yr | 5 Yr | 6 Yr | 7 Yr | 8 Yr | 9 Yr | 10 Yr | |
| Fund | -4.11% | -5.12% | 7.84% | -5.12% | 6.16% | 2.60% | 6.05% | 4.64% | 4.00% | 8.11% | 7.00% | 8.32% | 8.67% | 9.28% |
| Benchmark | -6.17% | -2.73% | 4.77% | -2.73% | 2.29% | 3.63% | 6.57% | 5.66% | 6.28% | 7.97% | 7.71% | 8.68% | 8.75% | 9.03% |
| Category Average | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Category Rank | 5 / 52 | 34 / 51 | 10 / 51 | 34 / 51 | 7 / 50 | 19 / 49 | 12 / 43 | 12 / 40 | 18 / 38 | 9 / 36 | 9 / 35 | 4 / 32 | 2 / 29 | 2 / 29 |
| Quartile Ranking | 1 | 3 | 1 | 3 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 1 |
| Return % | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund | -4.41% | -6.74% | 3.08% | 0.36% | 3.18% | 3.43% | 8.66% | 8.50% | -3.59% | -1.78% | 0.73% | -4.11% |
| Benchmark | -5.42% | -3.48% | 0.91% | -0.60% | 4.16% | 2.38% | 3.42% | 7.21% | -2.85% | 0.25% | 3.41% | -6.17% |
12.68% (April 2020)
-13.03% (January 2016)
| Return % | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Fund | -14.45% | 18.34% | 8.41% | 21.49% | 25.13% | 10.36% | -7.08% | 0.16% | 9.36% | 11.73% |
| Benchmark | -8.68% | 14.01% | 11.82% | 17.06% | 13.59% | 15.28% | -1.72% | 1.42% | 9.95% | 9.64% |
| Category Average | - | - | - | - | - | - | - | - | - | - |
| Quartile Ranking | 3 | 1 | 2 | 1 | 1 | 3 | 3 | 3 | 2 | 2 |
| Category Rank | 17/ 29 | 3/ 29 | 10/ 32 | 5/ 34 | 3/ 35 | 26/ 38 | 30/ 40 | 26/ 41 | 18/ 48 | 14/ 50 |
25.13% (2020)
-14.45% (2016)
| Name | Percent |
|---|---|
| US Equity | 87.49 |
| International Equity | 11.53 |
| Cash and Equivalents | 0.68 |
| Foreign Corporate Bonds | 0.31 |
| Name | Percent |
|---|---|
| Healthcare | 91.49 |
| Consumer Services | 0.87 |
| Cash and Cash Equivalent | 0.68 |
| Fixed Income | 0.31 |
| Other | 6.65 |
| Name | Percent |
|---|---|
| North America | 88.47 |
| Europe | 9.44 |
| Latin America | 1.13 |
| Asia | 0.91 |
| Africa and Middle East | 0.01 |
| Other | 0.04 |
| Name | Percent |
|---|---|
| Eli Lilly and Co | 10.17 |
| Thermo Fisher Scientific Inc | 4.07 |
| Intuitive Surgical Inc | 3.68 |
| Stryker Corp | 3.48 |
| Merck & Co Inc | 3.45 |
| AstraZeneca PLC | 3.18 |
| UnitedHealth Group Inc | 3.10 |
| argenx SE - ADR | 2.92 |
| Abbvie Inc | 2.86 |
| Regeneron Pharmaceuticals Inc | 2.67 |
TD Health Sciences Fund - D-Series
Median
Other - Health Care Equity
| Standard Deviation | 13.49% | 14.04% | 14.52% |
|---|---|---|---|
| Beta | 1.07% | 1.08% | 1.11% |
| Alpha | -0.01% | -0.02% | 0.00% |
| Rsquared | 0.82% | 0.81% | 0.79% |
| Sharpe | 0.23% | 0.15% | 0.56% |
| Sortino | 0.44% | 0.19% | 0.77% |
| Treynor | 0.03% | 0.02% | 0.07% |
| Tax Efficiency | 100.00% | 100.00% | - |
| Volatility |
|
|
|
| Key Ratio | 1 Yr | 3 Yr | 5 Yr | 10 Yr |
|---|---|---|---|---|
| Standard Deviation | 17.25% | 13.49% | 14.04% | 14.52% |
| Beta | 1.06% | 1.07% | 1.08% | 1.11% |
| Alpha | 0.04% | -0.01% | -0.02% | 0.00% |
| Rsquared | 0.77% | 0.82% | 0.81% | 0.79% |
| Sharpe | 0.29% | 0.23% | 0.15% | 0.56% |
| Sortino | 0.42% | 0.44% | 0.19% | 0.77% |
| Treynor | 0.05% | 0.03% | 0.02% | 0.07% |
| Tax Efficiency | 100.00% | 100.00% | 100.00% | - |
| Start Date | October 20, 2015 |
|---|---|
| Instrument Type | Mutual Fund |
| Share Class | Do-It-Yourself |
| Legal Status | Trust |
| Sales Status | Open |
| Currency | CAD |
| Distribution Frequency | Annual |
| Assets ($mil) | $1,214 |
| FundServ Code | Load Code | Sales Status |
|---|---|---|
| TDB3099 |
The fundamental investment objective of the Fund is to achieve long-term capital appreciation by investing primarily in equity securities of companies located in the United States and other countries, that are engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences.
The sub-adviser seeks to achieve the fundamental investment objective of the Fund by investing at least 65% of the Fund’s total assets in common stocks of companies in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences. The sub-adviser divides the health sciences sector into four main areas: pharmaceuticals, health care services, products and devices, and biotechnology firms.
| Portfolio Manager |
TD Asset Management Inc. |
|---|---|
| Sub-Advisor |
T. Rowe Price Associates, Inc.
|
| Fund Manager |
TD Asset Management Inc. |
|---|---|
| Custodian |
CIBC Mellon Trust Company |
| Registrar |
The Toronto-Dominion Bank |
| Distributor |
TD Investment Services Inc |
| RSP Eligible | Yes |
|---|---|
| PAC Allowed | Yes |
| PAC Initial Investment | - |
| PAC Subsequent | - |
| SWP Allowed | Yes |
| SWP Min Balance | 10,000 |
| SWP Min Withdrawal | 100 |
| MER | 1.61% |
|---|---|
| Management Fee | 1.25% |
| Load | No Load |
| FE Max | - |
| DSC Max | - |
| Trailer Fee Max (FE) | - |
| Trailer Fee Max (DSC) | - |
| Trailer Fee Max (NL) | 0.00% |
| Trailer Fee Max (LL) | - |
Try Fund Library Premium
For Free with a 30 day trial!
Fund Library
